MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc.'s (CXM) Generx® Addresses Global Cardiac Threat With Revolutionary Potential 0 comments
    Oct 25, 2013 4:05 PM | about stocks: CXM

    Cardium Therapeutics has developed a unique portfolio of businesses and product opportunities in the fields of health sciences and regenerative medicine. Among other opportunities in its portfolio, the company's lead clinical development product candidate, Generx®, is being developed to treat patients with advanced coronary artery disease (NYSEARCA:CAD). The market for this disease is tremendous - in 2012, CAD was the most common cause of death in the world, according to the World Health Organization.

    While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.

    Cardium's focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don't have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.

    Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate's capability to elicit blood vessel growth greatly contrasts traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.

    Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.

    For more information visit cardiumthx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.